No 04 2018

The two companies will advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD), including alpha-mannosidosis (aMann) and Krabbe disease (KD), ultra-rare diseases that affect the central nervous system.

25 new researchers from all over the world will hopefully arrive in Lund this autumn.

Based on new geroscience findings, many of the diseases that emerge later on in life could be prevented if the aging process could be slowed down.

Swedish Mavatar has announced the opening of its first US office and the upcoming commercial launch of its platform Mavatar Discovery.

The phase 2a proof-of-concept DELTA NEXT trial aims to evaluate the efficacy and safety of delgocitinib cream compared to cream vehicle in the treatment of adults with mild to severe Palmoplantar Pustulosis (PPP).

The company has appointed Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025.

The University of Oxford and ReciBioPharm, Recipharm’s Advanced Biologics division are expanding their collaboration with the development of two blood-stage malaria vaccine candidates for Phase 1/2 clinical trials.